Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 4/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.43 |
| ▸ | TCF7 | P36402 | 2/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.43 |
| ▸ | TCF4 | P15884 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14620563 | 0.96 | CYP3A4 (0.50) | CLPPCYP3A4CTNNB1TCF7BCL9 | |
| SCHEMBL748616 | 0.96 | CYP3A4 (0.45) | CLPPCYP3A4 | |
| SCHEMBL747086 | 0.95 | CLPP (0.45) | CLPPSIRT5CYP3A4CTNNB1TCF7 | |
| SCHEMBL747224 | 0.95 | CLPP (0.45) | CLPPSIRT5CYP3A4CTNNB1TCF7 | |
| SCHEMBL747397 | 0.95 | SIRT5 (0.49) | CLPPSIRT5CYP3A4CACNA1GCACNA1H | |
| SCHEMBL749649 | 0.93 | MEN1 (0.50) | CLPPCYP3A4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL10224825 | 0.93 | CLPP (0.45) | CLPPSIRT5CYP3A4CACNA1GCACNA1H | |
| SCHEMBL747284 | 0.93 | MEN1 (0.50) | CLPPCYP3A4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL748605 | 0.93 | CLPP (0.43) | CLPPSIRT5CYP3A4CTNNB1TCF7 | |
| SCHEMBL745669 | 0.92 | CLPP (0.49) | CLPPCYP3A4CTNNB1TCF7BCL9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2015-02-26 | — | — | US | disclosed |
| US-8729262-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729262-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8318738-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-11-27 | — | — | US | disclosed |
| US-8318738-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-11-27 | — | — | US | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8106049-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | Chongwae Pharma Corporation (KR) | 2010-02-04 | — | — | US | disclosed |
| US-7585862-B2 | Colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss | CHOONGWAE PHARMA CORPORATION (KR) | 2009-09-08 | — | — | US | disclosed |
| US-7585862-B2 | Colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss | CHOONGWAE PHARMA CORPORATION (KR) | 2009-09-08 | — | — | US | disclosed |
| US-7576084-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-08-18 | — | — | US | disclosed |
| US-7576084-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-08-18 | — | — | US | disclosed |
| US-7566711-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-07-28 | — | — | US | disclosed |
| US-7566711-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-07-28 | — | — | US | disclosed |
| US-7232822-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-06-19 | — | — | US | disclosed |
| US-7232822-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-06-19 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CLPP 4096/4885SIRT5 4437/4885CYP3A4 4757/4885 |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CLPP 4096/4885SIRT5 4437/4885CYP3A4 4757/4885 |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CLPP 4096/4885SIRT5 4437/4885CYP3A4 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.